Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$88.82 USD

88.82
5,887,528

+0.53 (0.60%)

Updated Oct 31, 2024 04:00 PM ET

Pre-Market: $88.51 -0.31 (-0.35%) 9:26 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Gilead Sciences (GILD) closed at $66.19 in the latest trading session, marking a -1.88% move from the prior day.

Court Ruling Topples Trump Order, No Price Display in TV Ads

by Zacks Equity Research

The recent ruling by a federal court against the Trump regime's decree to disclose the price labels of drugs in TV adverts resumes the spotlight on drug pricing.

Nilanjan Banerjee headshot

Will Patent Woes Boost Pharma Stock Megamergers Further?

by Nilanjan Banerjee

With key drugs losing exclusivity, key drug makers are poised to face deep trouble since their sales are mostly dependent on a single drug.

Glaxo's Long-Acting HIV Regimen Gets FDA's Priority Status

by Zacks Equity Research

Glaxo's (GSK) long-acting, injectable two-drug regimen gets FDA's priority review designation. The company begins study to identify approaches to implementing once-monthly injectable HIV treatment in the real world.

Gilead Sciences (GILD) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Gilead Sciences (GILD) closed at $69 in the latest trading session, marking a +0.23% move from the prior day.

Gilead to Submit NDA for Inflammation Drug Filgotinib in '19

by Zacks Equity Research

Gilead (GILD) is planning to submit regulatory application to the FDA seeking approval for filgotinib as a treatment for rheumatoid arthritis.

Regeneron/Sanofi's Libtayo Gets EU Approval for Skin Cancer

by Zacks Equity Research

Regeneron (REGN) wins approval for skin cancer drug, Libtayo, in the European Union.

Regeneron/Sanofi's Dupixent Gets Positive CHMP Recommendation

by Zacks Equity Research

Regeneron's (REGN) Dupixent gets favorable recommendation from CHMP for moderate-to-severe atopic dermatitis in adolescents aged 12-17 years.

Has Gilead Sciences (GILD) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (GILD) Outperforming Other Medical Stocks This Year?

Alexion Receives FDA Approval for Label Expansion of Soliris

by Zacks Equity Research

Alexion (ALXN) obtains FDA approval for Soliris for the treatment of neuromyelitis optica spectrum disorder.

Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Gilead Sciences (GILD) closed at $67.08 in the latest trading session, marking a +0.6% move from the prior day.

Zacks Market Edge Highlights: Facebook, Gilead, Disney, Grubhub and Microsoft

by Zacks Equity Research

Zacks Market Edge Highlights: Facebook, Gilead, Disney, Grubhub and Microsoft

Regeneron & Sanofi Get FDA Nod for Dupixent Label Expansion

by Zacks Equity Research

Regeneron (REGN) and partner Sanofi obtain FDA approval for Dupixent for the treatment of chronic rhinosinusitis with nasal polyposis in adults.

Tracey Ryniec headshot

5 Game Changing M&A Deals of the Last Decade

by Tracey Ryniec

M&A deals are usually ignored, or sometimes even openly mocked, but it can lead to an earnings and revenue renaissance. Did you spot these?

Biotech Stock Roundup: Vertex, AMAG Drugs Get FDA Nod, Conatus Study Fails & More

by Zacks Equity Research

Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.

Gilead Inks Deal With Carna Biosciences for Immuno-Oncology

by Zacks Equity Research

Gilead (GILD) teams up with Carna Biosciences to develop and commercialize small molecule compounds in immuno-oncology.

Gilead Sciences (GILD) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Gilead Sciences (GILD) closed at $69.38 in the latest trading session, marking a +1.18% move from the prior day.

Ekta Bagri headshot

3 Big Biotechs Hold Growth Potential in Second Half of 2019

by Ekta Bagri

We highlight a few leading players from the biotech sector, having surpassed the same so far in 2019 and are likely to put up a good show during the second half of 2019 as well.

Arbutus Gets Clearance to Initiate Hepatitis Study, Stock Up

by Zacks Equity Research

Arbutus (ABUS) surges on clearance for a clinical study to evaluate its RNAi agent, AB-729 as a treatment for hepatitis B virus.

Gilead (GILD) Teams Up With Nurix for Cancer and Other Drugs

by Zacks Equity Research

Gilead (GILD) collaborates with Nurix Therapeutics to leverage the proprietary drug discovery platform of the latter to identify novel agents that induce degradation of specified drug targets.

Kinjel Shah headshot

Big Drugmakers That May Tread the M&A Path After Pfizer

by Kinjel Shah

There has been a flurry of M&A deal announcements this year in the drug industry. Here we discuss three big drug/biotech companies, which may make the next M&A move.

AstraZeneca Gives Detailed Data From Calquence Leukemia Study

by Zacks Equity Research

AstraZeneca's (AZN) Calquence monotherapy prolongs progression-free survival significantly in relapsed or refractory CLL patients compared to Roche's Rituxan.

GILD vs. ILMN: Which Stock Is the Better Value Option?

by Zacks Equity Research

GILD vs. ILMN: Which Stock Is the Better Value Option?

Galapagos Ends Enrollment in Osteoarthritis Study Before Time

by Zacks Equity Research

Galapagos (GLPG) closes enrollment in the phase II study on GLPG1972/S201086 for the treatment of patients with osteoarthritis prior to the stipulated date.

CymaBay Down on Dismal Interim Data From Mid-Stage NASH Study

by Zacks Equity Research

CymaBay (CBAY) plummets as a phase IIb study on lead candidate, seladelpar, fails to show meaningful reductions in liver fat.